FDA Inspection
Asclemed USA Inc. dba Enovachem PharmaceuticalsAsclemed USA Inc. dba Enovachem Pharmaceuticals – FDA Inspection, Sep 27, 2018
Record Details
This FDA Inspection record concerns Asclemed USA Inc. dba Enovachem Pharmaceuticals, with an inspection on September 27, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- September 27, 2018
- Product Type
- Drugs
- People
- Rumany C. Penn (FDA Associated Person)
- Tamara L. Ely (Issuing Officer)
View Company Profile
ID · 6f1a6e9b-11cc-426d-aea3-aaa665e9f2a9
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1067059
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Asclemed USA Inc. dba Enovachem Pharmaceuticals
5| Date | Classification | Office | Project area |
|---|---|---|---|
| March 5, 2025 | Not classified | Los Angeles District Office | |
| November 5, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 12, 2017 | Not classified | Los Angeles District Office | Drug Quality Assurance |
| July 15, 2015 | VAI | Center for Drug Evaluation and Research | Unapproved and Misbranded Drugs |
| April 18, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Asclemed USA Inc. dba Enovachem Pharmaceuticals
- FDA Inspection 1263548 - 2025-03-05
- FDA Inspection 1111700 - 2019-11-05
- FDA Inspection 1029155 - 2017-10-12
- FDA Inspection 937934 - 2015-07-15
- FDA Inspection 828037 - 2013-04-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.